SCHEMBL2019668

SCHEMBL2019668

CCOC(=O)/C(=C/[C@H]1C[C@@H](F)[C@@H](F)C1)c1ccc(SC2CC2)cc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.33
PDE4B Q07343 1/20 0.32
ALDH1A1 P00352 3/20 0.31
GRIK1 P39086 1/20 0.31
MAPT P10636 2/20 0.31
KDM4E B2RXH2 1/20 0.31
GRIN1 Q05586 2/20 0.31
GRIN2B Q13224 2/20 0.31
NPC1 O15118 2/20 0.31
POLB P06746 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
MEN1 O00255 1/20 0.30
LMNA P02545 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30
KMT2A Q03164 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
PPM1B O75688 1/20 0.30
CTSS P25774 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2022151 1.00 RAB9A (0.33) RAB9APDE4BALDH1A1GRIK1MAPT
SCHEMBL2019670 1.00 RAB9A (0.33) RAB9APDE4BALDH1A1GRIK1MAPT
SCHEMBL2025888 1.00 RAB9A (0.33) RAB9APDE4BALDH1A1GRIK1MAPT
SCHEMBL2025889 1.00 RAB9A (0.33) RAB9APDE4BALDH1A1GRIK1MAPT
SCHEMBL2022153 1.00 RAB9A (0.33) RAB9APDE4BALDH1A1GRIK1MAPT
SCHEMBL2020632 0.87 ALDH1A1 (0.43) ALDH1A1MAPTKDM4EPOLBSMN1; SMN2
SCHEMBL2020630 0.87 ALDH1A1 (0.43) ALDH1A1MAPTKDM4EPOLBSMN1; SMN2
SCHEMBL4265493 0.87 RAB9A (0.37) RAB9APDE4BALDH1A1MAPTKDM4E
SCHEMBL16442454 0.87 ALDH1A1 (0.43) ALDH1A1MAPTKDM4EPOLBSMN1; SMN2
SCHEMBL4265499 0.87 RAB9A (0.37) RAB9APDE4BALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9452977-B2 Cyclopentylacrylamide derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2016-09-27 US disclosed
US-9452977-B2 Cyclopentylacrylamide derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2016-09-27 US disclosed
US-20150105581-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE TEIJIN LIMITED (JP) 2015-04-16 US disclosed
US-20150105581-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE TEIJIN LIMITED (JP) 2015-04-16 US disclosed
US-8946440-B2 Cyclopentylacrylamide derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2015-02-03 US disclosed
US-8946440-B2 Cyclopentylacrylamide derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2015-02-03 US disclosed
US-8946440-B2 Cyclopentylacrylamide derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2015-02-03 US disclosed
US-20110160211-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE TEIJIN LIMITED (JP) 2011-06-30 US disclosed
US-20110160211-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE TEIJIN LIMITED (JP) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160211-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE GPR119, SLC5A1, SLC5A2 RAB9A 2029/4885PDE4B 3188/4885ALDH1A1 606/4885
US-20150105581-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE GPR119, SLC5A1, SLC5A2 RAB9A 2029/4885PDE4B 3188/4885ALDH1A1 606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.